Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 May;40(5):1260–1262. doi: 10.1128/aac.40.5.1260

Increasing antibiotic resistance in clinical isolates of Aeromonas strains in Taiwan.

W C Ko 1, K W Yu 1, C Y Liu 1, C T Huang 1, H S Leu 1, Y C Chuang 1
PMCID: PMC163303  PMID: 8723478

Abstract

A total of 234 clinical isolates of Aeromonas, primarily A. hydrophila, were collected for the present study. Most were isolates from blood. By the agar dilution method, more than 90% of the Aeromonas strains were found to be susceptible to moxalactam, ceftazidime, cefepime, aztreonam, imipenem, amikacin, and fluoroquinolones, but they were more resistant to tetracycline, trimethoprim-sulfamethoxazole, some extended-spectrum cephalosporins, and aminoglycosides than strains from the United States and Australia.

Full Text

The Full Text of this article is available as a PDF (165.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbott S. L., Cheung W. K., Kroske-Bystrom S., Malekzadeh T., Janda J. M. Identification of Aeromonas strains to the genospecies level in the clinical laboratory. J Clin Microbiol. 1992 May;30(5):1262–1266. doi: 10.1128/jcm.30.5.1262-1266.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Carnahan A., Fanning G. R., Joseph S. W. Aeromonas jandaei (formerly genospecies DNA group 9 A. sobria), a new sucrose-negative species isolated from clinical specimens. J Clin Microbiol. 1991 Mar;29(3):560–564. doi: 10.1128/jcm.29.3.560-564.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chang B. J., Bolton S. M. Plasmids and resistance to antimicrobial agents in Aeromonas sobria and Aeromonas hydrophila clinical isolates. Antimicrob Agents Chemother. 1987 Aug;31(8):1281–1282. doi: 10.1128/aac.31.8.1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dryden M., Munro R. Aeromonas septicemia: relationship of species and clinical features. Pathology. 1989 Apr;21(2):111–114. doi: 10.3109/00313028909059546. [DOI] [PubMed] [Google Scholar]
  5. Fainstein V., Weaver S., Bodey G. P. In vitro susceptibilities of Aeromonas hydrophila against new antibiotics. Antimicrob Agents Chemother. 1982 Sep;22(3):513–514. doi: 10.1128/aac.22.3.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gold W. L., Salit I. E. Aeromonas hydrophila infections of skin and soft tissue: report of 11 cases and review. Clin Infect Dis. 1993 Jan;16(1):69–74. doi: 10.1093/clinids/16.1.69. [DOI] [PubMed] [Google Scholar]
  7. Iaconis J. P., Sanders C. C. Purification and characterization of inducible beta-lactamases in Aeromonas spp. Antimicrob Agents Chemother. 1990 Jan;34(1):44–51. doi: 10.1128/aac.34.1.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Janda J. M., Brenden R. Importance of Aeromonas sobria in Aeromonas bacteremia. J Infect Dis. 1987 Mar;155(3):589–591. doi: 10.1093/infdis/155.3.589. [DOI] [PubMed] [Google Scholar]
  9. Janda J. M., Duffey P. S. Mesophilic aeromonads in human disease: current taxonomy, laboratory identification, and infectious disease spectrum. Rev Infect Dis. 1988 Sep-Oct;10(5):980–997. doi: 10.1093/clinids/10.5.980. [DOI] [PubMed] [Google Scholar]
  10. Ko W. C., Chuang Y. C. Aeromonas bacteremia: review of 59 episodes. Clin Infect Dis. 1995 May;20(5):1298–1304. doi: 10.1093/clinids/20.5.1298. [DOI] [PubMed] [Google Scholar]
  11. Koehler J. M., Ashdown L. R. In vitro susceptibilities of tropical strains of Aeromonas species from Queensland, Australia, to 22 antimicrobial agents. Antimicrob Agents Chemother. 1993 Apr;37(4):905–907. doi: 10.1128/aac.37.4.905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kuijper E. J., Peeters M. F. Bacteriological and clinical aspects of Aeromonas-associated diarrhea in The Netherlands. Experientia. 1991 May 15;47(5):432–434. [PubMed] [Google Scholar]
  13. Morita K., Watanabe N., Kurata S., Kanamori M. beta-Lactam resistance of motile Aeromonas isolates from clinical and environmental sources. Antimicrob Agents Chemother. 1994 Feb;38(2):353–355. doi: 10.1128/aac.38.2.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Motyl M. R., McKinley G., Janda J. M. In vitro susceptibilities of Aeromonas hydrophila, Aeromonas sobria, and Aeromonas caviae to 22 antimicrobial agents. Antimicrob Agents Chemother. 1985 Jul;28(1):151–153. doi: 10.1128/aac.28.1.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Moyer N. P. Clinical significance of Aeromonas species isolated from patients with diarrhea. J Clin Microbiol. 1987 Nov;25(11):2044–2048. doi: 10.1128/jcm.25.11.2044-2048.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Moyer N. P., Geiss H. K., Marinescu M., Rigby A., Robinson J., Altwegg M. Media and methods for isolation of aeromonads from fecal specimens. A multilaboratory study. Experientia. 1991 May 15;47(5):409–412. [PubMed] [Google Scholar]
  17. Vukmir R. B. Aeromonas hydrophila: myofascial necrosis and sepsis. Intensive Care Med. 1992;18(3):172–174. doi: 10.1007/BF01709242. [DOI] [PubMed] [Google Scholar]
  18. Walsh T. R., Payne D. J., MacGowan A. P., Bennett P. M. A clinical isolate of Aeromonas sobria with three chromosomally mediated inducible beta-lactamases: a cephalosporinase, a penicillinase and a third enzyme, displaying carbapenemase activity. J Antimicrob Chemother. 1995 Feb;35(2):271–279. doi: 10.1093/jac/35.2.271. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES